文献速递血栓与止血

TPO受体激动剂时代重新审视脾切除治疗原发免疫性血小板减少症

Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment.
PubMed 文献 · Am J Hematol · 2021-10-26

该多中心回顾性研究纳入2011至2020年法国185例因ITP行脾切除的成人患者,评估脾切除在TPO-RA时代的疗效。结果显示总体持续缓解率65.4%,与TPO-RA前时代相似;对TPO-RA和利妥昔单抗均无效者中46%仍获持续缓解,脾切除后复发者对既往失败的TPO-RA再挑战61.2%有效。

要点

  • 脾切除治疗成人ITP总体持续缓解率65.4%,与TPO-RA前时代相似
  • 对TPO-RA和利妥昔单抗均无效者,脾切除后46%获持续缓解
  • 脾切除后复发者,对既往失败的TPO-RA再挑战61.2%有效

核心结论

  • 脾切除仍是治疗对TPO-RA和利妥昔单抗无效的成人原发ITP的合理选择。
  • 脾切除后无响应或复发者应重新试用TPO-RA。

研究设计与样本

  • 多中心回顾性研究,纳入2011至2020年法国因ITP行脾切除的成人患者185例。
  • 100例(54.1%)和135例(73.0%)患者在脾切除前接受过TPO-RA和/或利妥昔单抗。
  • 脾切除后中位随访39.2个月[16.5-63.0]。
  • 缓解状态按国际标准定义。

主要发现

  • 144例(77.8%)患者获初始缓解,23例(12.4%)随访期间复发,总体持续缓解率65.4%。
  • 脾切除前接受过至少一种TPO-RA或利妥昔单抗者中,92/151例(60.9%)获持续缓解。
  • 对TPO-RA和利妥昔单抗均无响应者中,6/13例(46%)脾切除后获持续缓解。
  • 脾切除后复发者中,13/21例(61.2%)对既往失败的TPO-RA有响应。

临床怎么用

  • 对TPO-RA和利妥昔单抗治疗无效的成人原发ITP,脾切除仍可作为治疗选项。
  • 脾切除后无响应或复发者,可重新试用TPO-RA。

局限性

  • 本研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although splenectomy is still considered the most effective curative treatment for immune thrombocytopenia (ITP), its use has significantly declined in the last decade, especially since the approval of thrombopoietin receptor agonists (TPO-RAs). The main objective of the study was to determine whether splenectomy was still as effective nowadays, particularly for patients with failure to respond to TPO-RAs. Our secondary objective was to assess, among patients who relapsed after splenectomy, the pattern of response to treatments used before splenectomy. This multicenter retrospective study involved adults who underwent splenectomy for ITP in France from 2011 to 2020. Response status was defined according to international criteria. We included 185 patients, 100 (54.1%) and 135 (73.0%) patients had received TPO-RAs and/or rituximab before the splenectomy. The median follow-up after splenectomy was 39.2 months [16.5-63.0]. Overall, 144 (77.8%) patients had an initial response and 23 (12.4%) experienced relapse during follow-up, for an overall sustained response of 65.4%, similar to that observed in the pre-TPO-RA era. Among patients who received at least one TPO-RA or rituximab before splenectomy, 92/151 (60.9%) had a sustained response. Six of 13 (46%) patients with previous lack of response to both TPO-RAs and rituximab had a sustained response to splenectomy. Among patients with relapse after splenectomy, 13/21 (61.2%) patients responded to one TPO-RAs that failed before splenectomy. In conclusion, splenectomy is still a relevant option for treating adult primary ITP not responding to TPO-RAs and rituximab. Patients with lack of response or with relapse after splenectomy should be re-challenged with TPO-RAs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mageau A, Terriou L, Ebbo M, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment. Am J Hematol. 2021. PMID: 34661954. doi:10.1002/ajh.26378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。